Hypercholesterolaemia - Pipeline Insight, 2021

This “Hypercholesterolaemia - Pipeline Insight, 2021” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hypercholesterolaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hypercholesterolaemia Understanding

Hypercholesterolaemia: Overview

Cholesterol is a component (a lipid or fat) that circulates in the bloodstream which the body uses to construct cells and produce certain substances that it needs. In this respect, its presence is both good and necessary. However, hypercholesterolaemia, or an excessive level or amount of cholesterol in the blood, can be harmful because it causes atheromatous plaques to deposit in the arteries (atherosclerosis). Therefore, it predisposes the development of cardiovascular diseases such as heart attacks, strokes or an insufficient blood supply to the limbs.

The need for treatment to reduce cholesterol levels must be individualised to each person and largely depends on the risk of suffering a cardiovascular event. There are several strategies to reduce cholesterol with medicines. For instance, there are drugs that decrease cholesterol production in the liver or which enable the liver to capture or “clean” more cholesterol from the blood. Statins are the treatment of choice and best-known drug therapy against hypercholesterolaemia. Ezetimibe acts by reducing cholesterol absorption in the intestine. Resins act in the intestine by promoting the elimination of bile which has a very high cholesterol content.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hypercholesterolaemia R&D. The therapies under development are focused on novel approaches for Hypercholesterolaemia.

Hypercholesterolaemia Emerging Drugs Chapters

This segment of the Hypercholesterolaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypercholesterolaemia Emerging Drugs

IBI306: Innovent Biologics

Tafolecimab (IBI306) is a recombinant fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) developed by Innovent for the treatment of hypercholesterolemia. PCSK9 binds the LDL-R/LDL-C complex and prevents LDL-R dissociation, make it to degrade with LDL-C and thus cannot circulate back to the hepatic cell surface. As the amount of LDL-R expression on the cell surface decreases, the level of LDL-C in the blood will accumulate and increase. Tafolecimab targets PCSK9 and inhibits its binding to LDL-R on the liver cell surface, maintaining the expression of LDL-R on the hepatocyte surface, thereby reducing LDL-C levels.

It is currently in Phase III stage of development for Hypercholesterolaemia and is being developed by Innovent Biologics.

AK-102: Akeso Biopharma

Ebronucimab (AK102) acts as inhibitors of PCSK9 protein. Ebronucimab (AK102) is being developed for the treatment of acquired and inherited hyperlipidemias, including HoFH, HeFH, and hypercholesterolemias patients with atherosclerotic cardiovascular disease.

It is currently in Phase II stage of development for Hypercholesterolaemia and is being developed by Akeso Biopharma.

Hypercholesterolaemia: Therapeutic Assessment

This segment of the report provides insights about the different Hypercholesterolaemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Hypercholesterolaemia

There are approx. 20+ key companies which are developing the Hypercholesterolaemia. The companies which have their Hypercholesterolaemia drug candidates in the most advanced stage, i.e. Phase III include, Innovent Biologics.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hypercholesterolaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypercholesterolaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypercholesterolaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypercholesterolaemia drugs.

Hypercholesterolaemia Report Insights

• Hypercholesterolaemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypercholesterolaemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing Hypercholesterolaemia drugs?
• How many Hypercholesterolaemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Hypercholesterolaemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypercholesterolaemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypercholesterolaemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Akeso Biopharma
• LIB Therapeutics
• Innovent Biologics
• Jiangsu HengRui Medicine
• AstraZeneca
• Vaxxinity

Key Products

• AK102
• IBI306
• Lerodalcibep
• SHR-1209
• AZD8233

Research programme: PCSK 9 inhibitor vaccine